Applied Biosystems Introduces Advanced Gene Expression Service Provider Program
Applied Biosystems (NYSE:ABI), an Applera Corporation business, today announced the introduction of the Applied Biosystems Advanced Gene Expression Service Provider Program, a new program for service providers who are interested in accessing Applied Biosystems comprehensive solution for gene expression analysis, including the highly sensitive Expression Array System for whole genome analysis and gold-standard TaqMan® Gene Expression Assays for target validation. The program includes a bundled product option for the entire gene expression workflow application and technical and promotional support that is expected to enhance service providers’ business offerings.
The program, intended to assist service providers in genetic analysis using interpretation tools and content to advance scientific research while helping them achieve necessary return on investment, was announced today in advance of this weekend’s annual World Microarray Congress in Vancouver, Canada.
The Applied Biosystems Expression Array System forms the technical platform for the program and can be optionally bundled with companion products that comprise Applied Biosystems’ whole solution for gene expression analysis, including microarrays for human, mouse, and rat, TaqMan® Gene Expression Assays, and Real-Time PCR Systems.
Additional data analysis and promotional support is included with the Applied Biosystems Advanced Gene Expression Service Provider Program. Participants will have access to the Celera Discovery System™ Online Platform and Panther™ Protein Classification System, a Service Provider web link on the Applied Biosystems Web site, and on-site seminars to educate customers to help provide increased business opportunities.
“Under the program, organizations offering gene expression analysis services can now offer their clients a complete gene expression analysis system backed with technical and promotional support package from the leader in gene expression technologies,” said Catherine M. Burzik, President of Applied Biosystems.
The Applied Biosystems Expression Array System is a highly sensitive gene expression detection system. The system detects more genes and achieves more than a 10-fold increase in sensitivity while using less sample for the detection of genes expressed at very low levels compared with conventional fluorescent microarrays. The system uses a chemiluminescence-detection instrument, software, and chemistries to deliver unambiguous gene results that are highly sensitive and reproducible.
The PCR process and the 5′ nuclease detection process are covered by patents owned by Roche Molecular System, Inc. and F. Hoffmann-La Roche Ltd (“Roche”). Performing services using these patented processes may require additional licenses from Applied Biosystems or Roche.
For more information, visit http://docs.appliedbiosystems.com/pebiodocs/00114098.pdf .
About Applera Corporation and Applied Biosystems
Applera Corporation consists of two operating groups. The Applied Biosystems Group serves the life science industry and research community by developing and marketing instrument-based systems, consumables, software, and services. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, develop new pharmaceuticals, and conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.7 billion during fiscal 2004. The Celera Genomics Group (NYSE:CRA) is engaged principally in the discovery and development of targeted therapeutics for cancer, autoimmune and inflammatory diseases. Celera Genomics is leveraging its proteomic, bioinformatic, and genomic capabilities to identify and validate drug targets, and to discover and develop small molecule therapeutics. It is also seeking to advance therapeutic antibody and selected small molecule drug programs in collaboration with global technology and market leaders. Celera Diagnostics, a 50/50 joint venture between Applied Biosystems and Celera Genomics, is focused on discovery, development, and commercialization of diagnostic products. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.applera.com , or by telephoning 800.762.6923. Information about Applied Biosystems is available at http://www.appliedbiosystems.com/ .
